JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $30.00.
Soumit Roy’s rating is based on the promising developments in Precision BioSciences’ gene editing programs, particularly the PBGENE-HBV and PBGENE-DMD assets. The company has started releasing clinical data for PBGENE-HBV, showing potential in treating chronic Hepatitis B, with significant reductions in Hepatitis B surface antigen observed in early trials. Additionally, the PBGENE-DMD program is positioned as a potential business development opportunity, with the possibility of entering clinical trials independently by the first half of 2026.
Furthermore, the financial projections for PBGENE-HBV indicate a substantial market opportunity, with estimated peak sales of $600 million worldwide by 2040. This is based on a conservative market penetration estimate and the prevalence of chronic Hepatitis B in the U.S. The absence of significant adverse events in initial trials also supports the positive outlook. These factors collectively contribute to the Buy rating, with a price target of $30.
In another report released on March 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.